Obstructive sleep apnea and the risk of gout: a population-based case-control study.
Case-control study
Comorbidity
Gout
Obstructive sleep apnea (OSA)
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
25 04 2020
25 04 2020
Historique:
received:
07
10
2019
accepted:
31
03
2020
entrez:
27
4
2020
pubmed:
27
4
2020
medline:
13
4
2021
Statut:
epublish
Résumé
Patients with obstructive sleep apnea (OSA) might be at risk of gout because of pathophysiological mechanisms that can lead to hyperuricemia and eventually gout or because of shared risk factors between both diseases. The objective of the present study was to investigate the risk of gout in patients with OSA. A population-based case-control study using the UK Clinical Practice Research Datalink GOLD including all patients aged 40 years and older with a first diagnosis of gout between 1987 and 2014. Gout cases were matched by year of birth, sex, and practice to non-gout controls. Conditional logistic regression estimated the risk of gout with an earlier diagnosis of OSA. Analyses were adjusted for lifestyle factors, comorbidities, and recent drug use. One hundred eleven thousand five hundred nine cases were matched with 210,241 controls. Patients with OSA were at increased risk of gout (OR 1.86; 95%CI (1.71-2.02). However, this association disappeared (OR 1.05; 95% CI 0.96-1.16) after adjustment for smoking status, body mass index (BMI), alcohol use, a history of heart failure, diabetes mellitus, renal function, and recent use of diuretics and other medications. Among females with OSA and patients with OSA associated with heart failure, renal impairment, or higher BMI, the risk of gout was however still increased when compared to the total control population. This study showed that the observed association between OSA and gout disappeared after adjustment.
Sections du résumé
BACKGROUND
Patients with obstructive sleep apnea (OSA) might be at risk of gout because of pathophysiological mechanisms that can lead to hyperuricemia and eventually gout or because of shared risk factors between both diseases. The objective of the present study was to investigate the risk of gout in patients with OSA.
METHODS
A population-based case-control study using the UK Clinical Practice Research Datalink GOLD including all patients aged 40 years and older with a first diagnosis of gout between 1987 and 2014. Gout cases were matched by year of birth, sex, and practice to non-gout controls. Conditional logistic regression estimated the risk of gout with an earlier diagnosis of OSA. Analyses were adjusted for lifestyle factors, comorbidities, and recent drug use.
RESULTS
One hundred eleven thousand five hundred nine cases were matched with 210,241 controls. Patients with OSA were at increased risk of gout (OR 1.86; 95%CI (1.71-2.02). However, this association disappeared (OR 1.05; 95% CI 0.96-1.16) after adjustment for smoking status, body mass index (BMI), alcohol use, a history of heart failure, diabetes mellitus, renal function, and recent use of diuretics and other medications. Among females with OSA and patients with OSA associated with heart failure, renal impairment, or higher BMI, the risk of gout was however still increased when compared to the total control population.
CONCLUSION
This study showed that the observed association between OSA and gout disappeared after adjustment.
Identifiants
pubmed: 32334617
doi: 10.1186/s13075-020-02176-1
pii: 10.1186/s13075-020-02176-1
pmc: PMC7183677
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Références
J Card Fail. 2011 May;17(5):420-5
pubmed: 21549300
Am J Respir Crit Care Med. 2009 Oct 15;180(8):788-93
pubmed: 19644043
Circulation. 2001 Nov 13;104(20):2407-11
pubmed: 11705816
Ann Rheum Dis. 2008 Sep;67(9):1310-6
pubmed: 18178692
Med Hypotheses. 2012 Feb;78(2):349
pubmed: 22098723
BMC Nephrol. 2013 Jul 29;14:164
pubmed: 23895142
Sleep Breath. 2002 Jun;6(2):49-54
pubmed: 12075479
J Crit Care. 2012 Dec;27(6):737.e11-24
pubmed: 22699032
PLoS One. 2011 Apr 29;6(4):e19029
pubmed: 21559506
Biomed Res Int. 2016;2016:1764837
pubmed: 27699167
Eur J Intern Med. 2014 Jun;25(5):471-6
pubmed: 24793835
Br J Clin Pharmacol. 2010 Jan;69(1):4-14
pubmed: 20078607
Rheumatology (Oxford). 2008 Dec;47(12):1840-1
pubmed: 18854344
BMJ Open. 2012 Feb 15;2(1):e000282
pubmed: 22337813
Eur Respir J. 2009 Apr;33(4):907-14
pubmed: 19336593
BMC Musculoskelet Disord. 2012 Sep 21;13:180
pubmed: 22995041
Can Respir J. 2006 May-Jun;13(4):203-10
pubmed: 16779465
PLoS One. 2014 Aug 15;9(8):e104519
pubmed: 25126761
Can J Cardiol. 2015 Jul;31(7):898-908
pubmed: 26112300
Arthritis Rheumatol. 2019 Jan;71(1):154-160
pubmed: 30160059
Sleep. 2015 Feb 01;38(2):213-21
pubmed: 25409108
Nephrourol Mon. 2015 May 23;7(3):e27233
pubmed: 26290849
Epidemiology. 2009 Jul;20(4):488-95
pubmed: 19525685
Eur Heart J. 2011 Mar;32(6):712-20
pubmed: 21199831
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):999-1003
pubmed: 26213344
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Int J Cardiol. 2017 Feb 1;228:151-157
pubmed: 27865177
Chest. 2002 Nov;122(5):1686-94
pubmed: 12426272
Int J Epidemiol. 2005 Jun;34(3):680-7
pubmed: 15802377
Sci Rep. 2017 May 3;7(1):1429
pubmed: 28469154
J Rheumatol Suppl. 2014 Sep;92:9-14
pubmed: 25180123
Arthritis Rheumatol. 2015 Dec;67(12):3298-302
pubmed: 26477891
Medicine (Baltimore). 2015 Aug;94(32):e1358
pubmed: 26266391
Lipids Health Dis. 2014 Jul 12;13:113
pubmed: 25015267
Circ Heart Fail. 2010 Jan;3(1):73-81
pubmed: 19933411
Eur J Heart Fail. 2017 Sep;19(9):1119-1127
pubmed: 28008698
Rheumatology (Oxford). 2013 Jan;52(1):118-26
pubmed: 22989425
Br J Clin Pharmacol. 1997 Aug;44(2):175-8
pubmed: 9278205